Abstract
Normal menopause is associated with vascular endothelial dysfunction, an early stage of atherosclerosis. Drospirenone, a progestogen with anti-aldosterone activity, has been developed for menopausal hormone therapy in combination with 17-beta-estradiol. The effect of this continuous combined hormone regimen on vascular endothelial function is unknown.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
